Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 1: NNC0487-0111 in Obesity
NCT07339423Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Primary completion
- Jun 2029
- Modality
- Peptides, Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of amycretin in obesity, sponsored by Novo Nordisk. Started Feb 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07339423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339423.